Holen Sie sich die Stockscreener-App
28.53
2.56%
-0.75
Vorhandelsmarkt:
28.55
0.02
+0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss - Trefis
(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RARE stock reflects Ultragenyx cash position and recent clinical progress - Ad-hoc-news.de
Ultragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focus - Sahm
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talk - Moomoo
RARE stock rises after Ultragenyx reports strong Crysvita revenue growth and narrows quarterly loss - Ad-hoc-news.de
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Law firm probes Ultragenyx officers for alleged false statements on drug trial results - Pluang
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm
Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa
Ultragenyx releases 2025 impact report on rare disease work - Investing.com
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times
Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative
Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire
Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $72 - Moomoo
Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa
Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa
Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com
Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, G - The National Law Review
Ultragenyx 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds - The National Law Review
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story? - simplywall.st
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark - marketscreener.com
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell Midcap Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Dynamic Index - marketscreener.com
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
0.74%
3.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):